When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
98%before December
- before December98%▲ 6
- before 202798%▲ 6
- before April 202798%
Install
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
The odds
91%Before 2028
- Before 202891%
- Before October 202788%
- Before July 202787%
- Before Mar 1, 202766%
- Before Jan 1, 202719%▲ 2
How the odds have moved
Before 2028: 89% on Oct 20, 91% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Before 2028 | 91% | 87¢ | 94¢ | $1.06 | 1.1K | |
| Before October 2027 | 88% | 85¢ | 91¢ | $1.10 | 2.4K | |
| Before July 2027 | 87% | 85¢ | 89¢ | $1.12 | 8.7K | |
| Before Mar 1, 2027 | 66% | 62¢ | 69¢ | $1.45 | 4.6K | |
| Before Jan 1, 2027 | 19% | ▲ 2 | 17¢ | 21¢ | $4.76 | 9.8K |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, Compass Pathways' COMP360 Psilocybin, COMP360 Psilocybin
Search ›- Grandparenting Through a Mental Health Crisis: What Families Should Know About Treatment-Resistant DepressionImage by rawpixel.com on Magnific Learn how to recognize treatment-resistant depression in someone you love and what modern options, like TMS, actually involve. My friend Cathy noticed her son had stopped calling on Sundays. Not because he…
- Exploring Deep Brain Stimulation to Manage Treatment-Resistant DepressionBy Frederick Hitti, M.D., Ph.D., Neurological Surgery, UT Southwestern Newswise — For many people living with depression, medications, psychotherapy, and other treatments can be life-changing. Sometimes, standard therapies do not work for…
- Ketamine for Treatment-Resistant Depression: What You Need to KnowTreatment-resistant depression affects millions of Americans who have tried multiple antidepressants without finding relief. After cycling through different medications, therapy approaches, and lifestyle changes, many people feel like…
- Treatment-resistant depression identified as a distinct molecular subtypeOr 34,00€ After 66% tax deduction A study led by the Hospital del Mar Research Institute, the University of Brescia, and Paris Brain Institute, with the collaboration of partners in the PROMPT consortium coordinated by the University of…
- Single dose of psychedelic nasal spray reduced treatment-resistant depression symptoms for eight weeksJoint first authors David Feifel of the Kadima Neuropsychiatry Institute in La Jolla, California, and Mathieu Seynaeve of King’s College London, along with their colleagues, tested the nasal spray in patients with treatment-resistant…
- Understanding the Neurobiology of Treatment-Resistant DepressionWritten by Joao L. de Quevedo, MD, PhD The hypothalamic-pituitary-adrenal (HPA) axis, which governs the body’s stress response, is often dysregulated in TRD. Chronic overactivation of the HPA axis leads to elevated cortisol levels…
- One dose of psychedelic nasal spray eased depression for eight weeks, study findsA JAMA trial involving 193 adults with treatment-resistant depression found that a single dose of 5-MeO-DMT nasal spray, administered with psychological support, improved symptoms within a day, with benefits lasting throughout eight weeks…
- FDA OKs generic HIV prevention shot, widening access for lower-income countriesEd Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding…
- 1 Reason Compass Pathways Is Worth a Second Look This MonthCompass Pathways (CMPS -2.68%) could be just months away from bringing one of the first Food and Drug Administration (FDA)-approved psychedelic treatments to market. The company is developing COMP360, a synthetic version of psilocybin…
- AI and Virtual Reality Enter the Therapist’s OfficeVisual: Moment via Getty Images That voice was then, through virtual reality technology, rendered on a screen as an avatar. Over a series of sessions, a therapist would articulate the patient’s internal monologue: “You’re fat,” “You should…
- Rising Psychiatry Introduces Accelerated TMS Treatment for Depression in Steamboat SpringsHome » Health » Rising Psychiatry Introduces Accelerated TMS Treatment for Depression in Steamboat Springs In Steamboat Springs, the local community is gaining access to a groundbreaking treatment for depression through Rising Psychiatry…
- High-profile advocates are shining a light on innovative psychiatric protocolsIncreased open discourse regarding severe depression has led to greater interest in advanced medical treatments for resistant mental health conditions. Public discourse and advocacy are reducing social stigma around seeking advanced…
Related markets
All fda & drugs ›Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
14%chance▼ 2
Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 9, 2027even chance by
- Before Jan 1, 20272%▲ 1
- Before Jul 1, 202712%▼ 5
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
When will the FDA reclassify BPC-157 to Category 1?
10%Before 2027
- Before 202710%▲ 1
FDA decision: Vamikibart by Genentech (on or before July 31, 2027)
64%chance▲ 2
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
74%chance▼ 1
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues just now. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions